drugset / Trial / NCT00673322
Trial of Second Generation Designer T Cells in Colorectal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to collect data on the safety and effectiveness of 2nd generation designer T cells in patients with colorectal cancer. Designer T cells are prepared by collecting white blood cells from the participant, and then modifying these cells in the laboratory so that they recognize the tumor antigen (CEA). These modified cells are then given back into the participant so that they can attack and kill tumor cells.
Timeline
- Start
- 2008-05
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gene Modified T Cells | Cell therapy | 1e+09 cells | Intravenous |
| Subject | Gene Modified T Cells | Cell therapy | 1e+10 cells | Intravenous |
| Subject | Gene Modified T Cells | Cell therapy | 1e+11 cells | Intravenous |